Clinical trials: Platelet-Rich Fibrin (PRF)
Diabetic Foot Ulcers
Evaluation of the Effect of Vivostat Platelet Rich Fibrin(PRF) in the Treatment of Diabetic Foot Ulcers
Diabetic foot ulcers are a challenge to health care professionals because there are only few effective topical therapeutic interventions.
- Trial name
- NCT00770939
- Testing
- Vivostat PRF
- Where
- 5 sites in Denmark, Germany and 1 more
- Volunteers
- 60 people
- Sponsor
- Vivostat
Diabetic Foot Ulcer, Type 1 Diabetes Mellitus
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
The goal of this investigational study is to evaluate the safety and clinical performance of Tropocells Autologous Platelet-rich Fibrin (PRF) for wound care for both males and females, ages 18-80 years old, with Grade 1 and 2…
- Conditions
- Diabetic Foot Ulcer, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus (T2DM), Neuroischemic Foot Ulcer
- Trial name
- NCT06810726
- Testing
- Platelet Rich Plasma
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Estar Medical dba Medical Technologies, LTD
Wound Chronic Draining, Wound Closure
Using TropoCells(R) Autologous Platelet-Rich Fibrin (PRF) to Treat Chronic Non-Healing Wounds
Platelet-based therapies have been used to treat bony and soft tissue effects for more than 30 years. Tropocells® Autologous Platelet-Rich Fibrin (PRF) is being used to treat chronic, non-healing wounds, of a variety of types.
- Trial name
- NCT07318792
- Testing
- Platelet-rich fibrin (PRF)
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Estar Medical dba Medical Technologies, LTD